
ASCO 2019

X
ASCO 2019 round-up
https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-round-up/

X
ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial
https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/

X
ASCO 2019 – phase I data generates hope for the future
https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/

X
ASCO 2019 – Enfortumab comes out fighting in bladder cancer
https://pharmaphorum.com/video/asco-2019-enfortumab-bladder-cancer/

X
ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II results
https://pharmaphorum.com/video/asco-2019-results-clinical-practices-changing-phase-iii-studies/

X
Sanofi trumpets Darzalex rival isatuximab in refractory myeloma
https://pharmaphorum.com/news/sanofi-darzalex-rival-isatuximab-refractory-myeloma/

X
ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial
https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-debate-results-from-keynote-062-trial/